NeOnc Technologies (NTHI) vs Tenax Therapeutics (TENX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Tenax Therapeutics (TENX) has outperformed NeOnc Technologies (NTHI) over the past year, losing 76.2% versus a loss of 79.1%. NeOnc Technologies is the larger company by market cap ($77.5 million vs $68.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NTHI | TENX |
|---|---|---|
| Share price | $2.69 | $1.83 |
| Market cap | $77.49M | $68.30M |
| 1-day change | +6.32% | -1.88% |
| YTD return | -69.41% | -84.74% |
| 1-year return | -79.07% | -76.25% |
| 5-year return | — | -99.93% |
| EPS (TTM) | $-2.13 | $-1.48 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.09 | $19.40 |
| 52-week low | $2.50 | $1.31 |
| Distance from 52-week high | -77.75% | -90.59% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +531.97% | +588.22% |
| Average volume | 195.17K | 5.46M |
| Shares outstanding | 28.81M | 37.42M |
| Employees | 5 | 14 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About NeOnc Technologies
NTHI stock →NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About Tenax Therapeutics
TENX stock →Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
NTHI vs TENX FAQ
Which is bigger, NeOnc Technologies or Tenax Therapeutics?
NeOnc Technologies (NTHI) is larger, with a market capitalization of $77.49M compared with $68.30M for Tenax Therapeutics (TENX).
Which stock has performed better over the past year, NTHI or TENX?
TENX returned -76.25% over the past 12 months, compared with -79.07% for NTHI (price return, excluding dividends). Past performance does not predict future results.
Are NeOnc Technologies and Tenax Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.